Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
King Pharmaceuticals has decided to discontinue the manufacturing of Intal Inhaler (cromolyn sodium inhalation aerosol). This decision is based on King’s inability to identify a qualified manufacturer for chlorofluorocarbon propellant inhalers and to reformulate Intal to a chlorofluorocarbon-free or hydrofluoroalkane (HFA) propellant formulation. Intal Inhaler will remain available through pharmacies and wholesalers until current supplies are depleted. Healthcare professionals are being notified to transition patients currently using Intal to alternative therapies.
Intal is a prophylactic agent indicated in the management of patients with bronchial asthma.
For more information please call (800) 776-3637 or visit http://www.fda.gov/downloads/Drugs/DrugSafety/DrugShortages/UCM175032.pdf
